6 Ways to Elevate Your Machine Translation Strategy

Future-proof your MT strategy for clinical and regulatory content with this guide.

AI Driven

With 2025 well underway, innovators in the global life sciences and pharmaceutical industries continue to question how to maximize efficiencies and reduce complexities in clinical and regulatory content development and localization. As part of the broader technological roadmap, AI and automation remain front and center as key players in taking these workflows to new heights. Here are six approaches to ensure you don’t miss a pivotal step when adapting and applying your process.

translation_factory

1. Translation Model Customization

The pharmaceutical industry commands precision and optimal quality in all content. MT models should therefore be tailored and regularly updated such that they align with industry-specific terminology and have built-in glossaries that enforce accuracy and consistency across all translated materials. Using translation memories (TMs) and engine customization with company-specific data enables teams to repurpose pre-approved translations to cut down on review cycle times and ensure content uniformity when compared to “off-the-shelf” machine translation models.

Learn more about how machine translation drives success ›

2. Integration with Clinical & Regulatory Technologies

From a workflow perspective, MT can be integrated directly into additional content repositories, like an eTMF, RIM, web CMS, and more. This generates faster and more secure MT workflows that can be initiated from those same systems where your documents are authored and stored, in a secure “closed loop” ecosystem. In addition, integration with technologies like generative AI and natural language processing can yield more sophisticated language understanding and translation than MT alone. Explore 5 essential use cases for AI automation in regulatory content.

clinical_practice
contact

3. Increased Use of Multimodal Translation

With continually evolving capabilities and new use cases being identified, MT may extend beyond text to include multimodal elements, such as translating audio, images, graphs, and other visual content commonly found in pharmaceutical documents. This could enhance the overall translation of complex information and provide significant efficiencies in areas like patient recruitment and medical information, which more frequently utilize multi-channel and non-document-based content.

4. Enhanced Post-Editing Automation

Automation of post-editing processes has become more sophisticated, mitigating the need for extensive human intervention post-MT. Generative AI tools embedded within the review module leveraged by post-editors results in more streamlined workflows and rapid delivery of high-quality, fully reviewed translations.

post_editing
Forrester TEI GlobalLink for Life Sciences

5. Compliance Monitoring and Reporting

MT systems have evolved to incorporate multifaceted tools, such as built-in compliance monitoring features, ensuring that translations comply with specific regulatory requirements through automated checks for terminology consistency and language compliance, for example.

Key steps for regulatory submissions ›

6. Real-Time Collaboration Tools

The integration of real-time collaboration tools within MT platforms enhances efficiency and enables global teams to work simultaneously on translation projects. Features like live editing, instant feedback, and collaborative workflows help cut down the time needed to make documents submission-ready.

discussion regulatory

Additional Resources & Expert Perspectives

XTalks | eCOA: Has It Lived Up to the Promise? A Realistic Assessment for Today's Trials

Despite two decades of technological advancement, the debate between paper and electronic clinical outcome assessments (eCOA) remains unresolved. This webinar revisits the assumptions that continue to shape data collection strategies and examines whether current practice reflects today’s eCOA capabilities or institutional habit. Paper is often framed as the “gold standard,” yet paper-based patient-reported outcome data can be incomplete, error-prone and difficult to ...

XTalks | eCOA: Has It Lived Up to the Promise? A Realistic Assessment for Today's Trials
Success Stories

Top 10 Pharma Company Overhauls Global COA Program,Cutting Costs by 33% and Errors to Near Zero

Inconsistent standards, stretched timelines, and limited visibility were straining a top 10 pharma company's COA program. Discover how TransPerfect Life Sciences' centralization strategy delivered 99.7% accuracy, 40% less PM oversight, and 33% cost savings across the ...
Blog

Four Years In: What the EU Clinical Trial Regulation Has (and Hasn't) Delivered

When the EU Clinical Trial Regulation (EU CTR No 536/2014) went live for new submissions on January 31, 2022, it promised to transform how clinical trials are authorized and conducted across Europe: a single submission, one decision, and harmonized oversight. Four years in,...
Webinar

How to Make Your Academy Succeed at Global Scale—Lessons Learned on What Works and What Doesn’t

Most life sciences and MedTech companies launch a corporate academy with strong strategic intent, whether that’s executive sponsorship, a named platform, a dedicated budget, or a curriculum mapped to business goals. After launch, however, these same organizations all too often ...
Webinar

IMP Labeling Workflows That Reduce Relabeling Risk and Start-Up Delays

Investigational medicinal product (IMP) labeling sits at the heart of clinical trial supply, impacting departments across pharmaceutical organizations, from clinical operations and regulatory affairs to quality assurance and beyond. When labeling activities are managed across ...
Webinar

The Missing Link: Why Study Design Makes or Breaks a Clinical Trial

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Farrell Healion, Founder and Principal Consultant at OptiTrial, to explore why study design is so often the overlooked "missing link" in clinical ...
Event

C3 Summit 2026 - London

Conversations on Clinical Content, C3 Summit is part of a series of events hosted by TransPerfect Life Sciences featuring sessions with expert panels discussing present challenges, strategies, and innovations, as well as insights into future advancements, from R&D to ...

Reach out to our team of AI and MT experts to get started today.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.